arrow
A

Alessandra Iurlo

foundation irccs ca'granda ospedale maggiore policlinico
H指数:47
被引数:8,667

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib

欧洲白血病网络临床体征和症状作为在鲁索利替尼治疗期间真性红细胞增多症中的预后标志物

Leukemia
IF13.4
2026-11-170
OAAI
Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera

低剂量罗肽干扰素在低风险真性红细胞增多症中实现<i>JAK2V617F</i>分子反应的长期深化

2026-10-260
PRE
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Frontline nilotinib vs dasatinib in NEwly diagnosed chronic phase chronic myeloid leukemia: a propensity score analysis based on AIFA monitoring registries

一线尼洛替尼与达沙替尼在 newly diagnosed 慢性期慢性髓性白血病中的比较:基于 AIFA 监测登记研究的倾向性评分分析

2026-04-240
PRE
Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis

细胞减灭疗法对骨髓增生性肿瘤相关内脏静脉血栓形成的影响

2026-01-010
OA
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study

阐明慢性髓性白血病患者诊断时外周血白血病干细胞临床作用:FLOWERS前瞻性研究的最终结果

Cancer
IF5.1
2025-10-150
OAAI
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera

中性粒细胞与淋巴细胞比值作为JAK2V617F抑制和事件-free生存的替代指标在真性红细胞增多症中的应用

2025-08-060
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability

SETD2功能缺失是进展期慢性髓性白血病中的常见事件,并导致基因组不稳定。

2025-04-240
OAAI
Circulating Levels of PF4/CXCL4 in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression

BCR::ABL1阴性骨髓增殖性肿瘤患者中PF4/CXCL4的循环水平:疾病进展的一个新的潜在预后因素

2025-04-130
PRE
Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects

慢性期慢性髓性白血病(CP-CML)患者接受尼洛替尼治疗12个月后的骨髓CD34+/lin-细胞,其基因表达特征与诊断时及健康受试者对应的细胞存在差异。

CANCERS
IF4.4
2025-03-180
OA
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Ponatinib治疗在TKI不耐受患者中的长期安全性和有效性:意大利慢性粒细胞白血病患者Ponatinib治疗观察研究(OITI)的亚组分析

BLOOD
IF23.1
2024-11-050
PRE
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE